MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Moleculin Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.27−0.02 (-5.49%)
Close on Oct 19, 2026
- Market cap
- $1.51M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$12.4850 (−97.92%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Moleculin Biotech, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$22.74M.
Revenue
$0
TTM Q2 2026
Operating income
-$28.87M
TTM Q2 2026
Free cash flow
-$22.74M
FY2025
EPS, diluted
-$15.01
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.51M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.13
- Dividend yield
- –
- Free cash flow yield
- -1510.24%
Fundamentals
- Revenue
- $0
- Net income
- -$30.33M
- EPS, diluted
- -$15.01
- Free cash flow
- -$22.74M
- Book value per share
- $2.04
- Diluted shares
- 6M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
$0
Operating income
-$28.87M
Net income
-$30.33M
EPS, diluted
-$15.01
Free cash flow
–
Reported periodTrailing twelve months